Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
50 hedge funds and large institutions have $120M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
76% more capital invested
Capital invested by funds: $68.5M → $120M (+$51.8M)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
28% more funds holding
Funds holding: 39 → 50 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.1M |
| 3 |
Jennison Associates
New York
|
+$7.2M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
+$3.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.68M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$1.1M |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$534K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$522K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$452K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
51
Tekla Capital Management
Boston,
Massachusetts
| – | -$452K | -1,528 | Closed |
|
|
SM
52
Sabby Management
Miami Beach,
Florida
| – | -$317K | -1,073 | Closed |
|
53
DZ Bank
Frankfurt Am Main,
Germany
| – | -$227K | -769 | Closed |
|
|
WS
54
Wedbush Securities
Los Angeles,
California
| – | -$191K | -645 | Closed |
|
55
BNP Paribas Financial Markets
Paris,
France
| – | -$621 | -2 | Closed |
|
EIGR Hedge Fund Activity: Q2 2018 in Review
50 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2018, worth a combined $120M — up 76% from $68.5M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EIGR positions and 6 closed out — a net gain of 11 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $12.3M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $4.68M sold.
- 50 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2018, up from 39 in Q1 2018.
- Funds reported $120M of Eiger BioPharmaceuticals, Inc. stock for Q2 2018, up 76% quarter-over-quarter.
- 17 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2018 and 6 closed out, a net change of +11 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2018 was EcoR1 Capital, an estimated $12.3M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2018 was Sphera Funds Management, an estimated $4.68M sold.
Based on aggregated 13F filings for Q2 2018.